Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia.

ABSTRACT:

Background

Lysyl oxidase (LOX) has been described as necessary for premetastatic niche formation in epithelium-derived malignancies and its expression level therefore correlates with risk of metastatic disease and overall survival. However, its role in acute myeloid leukemia (AML) has not been sufficiently analyzed.

Methods

We investigated LOX plasma expression in 683 AML patients (age 17-60 years) treated within the prospective AML2003 trial (NCT00180102). The optimal cut-off LOX value was determined using a minimal-p-value method dichotomizing patients into a LOX-high group (> 109 ng/mL, n = 272, 40%) and a LOX-low group (≤ 109 ng/mL, n = 411, 60%).

Results

Higher LOX expression was associated with lower peripheral white blood cells, lower serum

SUBMITTER: Kunadt D 

PROVIDER: S-EPMC7291659 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature